Seres Therapeutics, Inc. (MCRB): who owns it and who trades it
As of Nov 12, 2026, MCRB insiders reported 12 open-market sales worth $10K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Eric D. Shaff (Director), with $5.3K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Seres Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MCRB
36 funds and institutions reported MCRB shares worth $18.2M at the end of Q2 2026, about 24% of the company. The largest holder is Flagship Pioneering, LLC with 12.1%.
Funds and institutions (13F) 24%Everyone else 76%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Flagship Pioneering, LLC | 1.16M | 12.06% | $9.1M | No change |
| Vanguard Capital Management LLC | 287,776 | 3.00% | $2.3M | -2% |
| Marshall Wace, LLP | 172,245 | 1.80% | $1.4M | +23% |
| Vontobel Holding Ltd. | 122,975 | 1.28% | $970K | -11% |
| BlackRock, Inc. | 111,000 | 1.16% | $876K | +9% |
| Geode Capital Management, LLC | 79,974 | 0.83% | $631K | +7% |
| Susquehanna International Group, LLP | 58,328 | 0.61% | $460K | -45% |
| Vanguard Fiduciary Trust Co | 48,685 | 0.51% | $384K | +23% |
| State Street Corp | 33,901 | 0.35% | $267K | No change |
| Lion Point Capital, LP | 31,570 | 0.33% | $249K | No change |
| Charles Schwab Investment Management Inc | 31,049 | 0.32% | $245K | -2% |
| Sixth Street Partners Management Company, L.P. | 31,049 | 0.32% | $245K | New |
| American Century Companies Inc | 28,313 | 0.30% | $223K | -55% |
| XTX Topco Ltd | 20,732 | 0.22% | $164K | New |
| Goldman Sachs Group Inc | 15,229 | 0.16% | $120K | New |
| Northern Trust Corp | 14,765 | 0.15% | $116K | No change |
| Invesco Ltd. | 12,974 | 0.14% | $102K | -11% |
| Morgan Stanley | 12,138 | 0.13% | $95.8K | -44% |
| Citadel Advisors LLC | 10,504 | 0.11% | $82.9K | New |
| Simplex Trading, LLC | 4,598 | 0.05% | $36.3K | +50% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MCRB insiders reported $0 of open-market purchases and $10K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Kelly Brady | See Remarks | Sale | 64 | $4.55 | $291 | Form 4 |
| Aug 17, 2026 | Eric D. Shaff | Director | Sale | 263 | $4.55 | $1.2K | Form 4 |
| Aug 17, 2026 | Matthew R Henn | See Remarks | Sale | 81 | $4.55 | $369 | Form 4 |
| Aug 17, 2026 | Thomas DesRosier | See Remarks | Sale | 82 | $4.55 | $373 | Form 4 |
| May 18, 2026 | Eric D. Shaff | Director | Sale | 259 | $7.53 | $2K | Form 4 |
| May 18, 2026 | Kelly Brady | See Remarks | Sale | 59 | $7.53 | $444 | Form 4 |
| May 18, 2026 | Thomas DesRosier | See Remarks | Sale | 79 | $7.53 | $595 | Form 4 |
| May 18, 2026 | Matthew R Henn | See Remarks | Sale | 77 | $7.53 | $580 | Form 4 |
| Feb 15, 2026 | Teresa L. Young | See Remarks | Sale | 75 | $8.47 | $635 | Form 4 |
| Feb 15, 2026 | Eric D. Shaff | Director | Sale | 259 | $8.47 | $2.2K | Form 4 |
| Feb 15, 2026 | Thomas DesRosier | See Remarks | Sale | 78 | $8.47 | $661 | Form 4 |
| Feb 15, 2026 | Matthew R Henn | See Remarks | Sale | 89 | $8.47 | $754 | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Eric D. Shaff | Director | – | $5.3K | Aug 17, 2026 |
| Matthew R Henn | See Remarks | – | $1.7K | Aug 17, 2026 |
| Thomas DesRosier | See Remarks | – | $1.6K | Aug 17, 2026 |
| Kelly Brady | See Remarks | – | $735 | Aug 17, 2026 |
| Teresa L. Young | See Remarks | – | $635 | Feb 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MCRB short interest
Low short interest. 3.4% of MCRB shares are sold short: about 1 share in 29. Over the last 12 reports the number of shares short went down 33%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 342,237 MCRB shares were sold short, 3.4% of the shares outstanding, up 9.6% from the report before. At the average daily volume of 79,475 shares, buying them all back would take about 4.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 342,237 | 3.44% | +10% | 79,475 | 4.3 |
| Oct 15, 2026 | 312,339 | 3.14% | -1% | 90,602 | 3.5 |
| Sep 30, 2026 | 314,264 | 3.16% | +4% | 61,066 | 5.2 |
| Sep 15, 2026 | 301,344 | 3.03% | -15% | 52,639 | 5.7 |
| Aug 31, 2026 | 356,541 | 3.59% | -3% | 58,386 | 6.1 |
| Aug 14, 2026 | 367,864 | 3.70% | +17% | 67,863 | 5.4 |
| Jul 31, 2026 | 314,545 | 3.28% | +4% | 53,094 | 5.9 |
| Jul 15, 2026 | 303,423 | 3.17% | +93% | 151,675 | 2.0 |
| Jun 30, 2026 | 157,327 | 1.64% | -28% | 118,979 | 1.3 |
| Jun 15, 2026 | 219,815 | 2.29% | -54% | 102,140 | 2.1 |
| May 29, 2026 | 478,817 | 4.99% | -7% | 30,846 | 15.5 |
| May 15, 2026 | 512,802 | 5.35% | -5% | 46,263 | 11.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Seres Therapeutics company events
Seres Therapeutics filed 12 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 26, 2026LeadershipMarella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc., resigned from her positions as Executive Vice President and Chief Financial Officer of the Company, effective November 15, 2026. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Aug 4, 2026AgreementSeres Therapeutics, Inc. entered into the Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC, a Delaware limited liability company, the purpose of which is to effect an early termination of one of the Company’s leases, reducing the Company’s ongoing annual… Filing
- Jul 8, 2026LeadershipAs reported below under Item 5.07 of this Current Report on Form 8-K (this “Current Report”), on July 8, 2026, Seres Therapeutics, Inc. reconvened its 2026 Annual Meeting of Stockholders, which had been adjourned from June 9, 2026 due to a lack of quorum. Filing
- Jul 8, 2026AnnouncementThe Company announced top-line results from an IST evaluating SER-155 in patients with irEC. The study (NCT06801067), conducted at MSK, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases, evaluated SER-155 in 15 patients with moderate-to-severe… Filing
- Jun 5, 2026AgreementSeres Therapeutics, Inc. entered into Amendment No. 1 to the Asset Purchase Agreement, dated as of August 5, 2024 (as previously amended by that certain Letter Agreement, dated September 30, 2024 and that certain Letter Agreement, dated December 31, 2024, the “Purchase Agreement”), by and between… Filing
- Jun 1, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Mar 16, 2026AnnouncementSeres Therapeutics, Inc. announced today that the Company’s 2026 annual meeting of stockholders has been scheduled for June 9, 2026. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Mar 2, 2026LeadershipThe Board of Directors of Seres Therapeutics, Inc. appointed Richard N. Kender, a current member of the Board, to serve as Executive Chair of the Board and as Interim Chief Executive Officer of the Company, Matthew Henn, Ph.D., the Company’s Chief Scientific Officer, to the additional role of… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Seres Therapeutics financials
Famous investors that hold MCRB
1 of the 50 well-known investors we track reported holding MCRB in their latest 13F filing. The largest position is Jim Simons's, worth $39.5K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 11,791 | $39.5K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Seres Therapeutics, Inc. (MCRB) stock
Who owns the most MCRB stock?
The largest reported owner of Seres Therapeutics, Inc. (MCRB) is Flagship Pioneering, LLC, with 12.1% of the company. In total, 36 funds and institutions reported holding MCRB at the end of Q2 2026, together about 24% of the shares. See the largest owners.
Are MCRB insiders buying or selling?
In the last 12 months, MCRB insiders reported no open-market purchases and 12 sales worth $10K. The latest trade was on Aug 17, 2026. See every trade.
What is the short interest in MCRB?
As of Oct 30, 2026, 342,237 MCRB shares were sold short, 3.4% of the shares outstanding, up 9.6% from the report before. At the average daily volume of 79,475 shares, buying them all back would take about 4.3 trading days (days to cover). See the history.
Which famous investors hold MCRB?
1 of the 50 well-known investors we track reported MCRB in their latest 13F filing, including Jim Simons. The largest position is worth $39.5K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.